Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.

Silvestri C, Paris D, Martella A, Melck D, Guadagnino I, Cawthorne M, Motta A, Di Marzo V.

J Hepatol. 2015 Jun;62(6):1382-90. doi: 10.1016/j.jhep.2015.01.001. Epub 2015 Jan 13.

PMID:
25595882
2.

Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review.

McPartland JM, Duncan M, Di Marzo V, Pertwee RG.

Br J Pharmacol. 2015 Feb;172(3):737-53. doi: 10.1111/bph.12944. Review.

3.

Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.

De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, Di Marzo V.

Acta Physiol (Oxf). 2012 Feb;204(2):255-66. doi: 10.1111/j.1748-1716.2011.02338.x. Epub 2011 Aug 12.

PMID:
21726418
4.

Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.

Zhong D, Xie Z, Huang B, Zhu S, Wang G, Zhou H, Lin S, Lin Z, Yang B.

Cell Physiol Biochem. 2018;49(3):1163-1179. doi: 10.1159/000493297. Epub 2018 Sep 7.

5.

Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action.

Maione S, Piscitelli F, Gatta L, Vita D, De Petrocellis L, Palazzo E, de Novellis V, Di Marzo V.

Br J Pharmacol. 2011 Feb;162(3):584-96. doi: 10.1111/j.1476-5381.2010.01063.x.

6.

Pharmacology of cannabinoids in the treatment of epilepsy.

Gaston TE, Friedman D.

Epilepsy Behav. 2017 May;70(Pt B):313-318. doi: 10.1016/j.yebeh.2016.11.016. Epub 2017 Jan 10. Review.

PMID:
28087250
7.

Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice.

Chao J, Huo TI, Cheng HY, Tsai JC, Liao JW, Lee MS, Qin XM, Hsieh MT, Pao LH, Peng WH.

PLoS One. 2014 Jun 11;9(2):e96969. doi: 10.1371/journal.pone.0096969. eCollection 2014.

8.

Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.

De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P, Di Marzo V.

Br J Pharmacol. 2013 Jan;168(1):79-102. doi: 10.1111/j.1476-5381.2012.02027.x.

9.

Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells.

Juknat A, Pietr M, Kozela E, Rimmerman N, Levy R, Coppola G, Geschwind D, Vogel Z.

Br J Pharmacol. 2012 Apr;165(8):2512-28. doi: 10.1111/j.1476-5381.2011.01461.x.

10.

Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour.

Deiana S, Watanabe A, Yamasaki Y, Amada N, Arthur M, Fleming S, Woodcock H, Dorward P, Pigliacampo B, Close S, Platt B, Riedel G.

Psychopharmacology (Berl). 2012 Feb;219(3):859-73. doi: 10.1007/s00213-011-2415-0. Epub 2011 Jul 28.

PMID:
21796370
11.

Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.

Espejo-Porras F, Fernández-Ruiz J, Pertwee RG, Mechoulam R, García C.

Neuropharmacology. 2013 Dec;75:155-63. doi: 10.1016/j.neuropharm.2013.07.024. Epub 2013 Aug 4.

PMID:
23924692
12.

The non-psychoactive plant cannabinoid, cannabidiol affects cholesterol metabolism-related genes in microglial cells.

Rimmerman N, Juknat A, Kozela E, Levy R, Bradshaw HB, Vogel Z.

Cell Mol Neurobiol. 2011 Aug;31(6):921-30. doi: 10.1007/s10571-011-9692-3. Epub 2011 Apr 30.

PMID:
21533611
13.

Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors.

Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J.

Eur J Neurosci. 2007 Aug;26(4):843-51. Epub 2007 Aug 2.

PMID:
17672854
14.

Compartmentalization of endocannabinoids into lipid rafts in a microglial cell line devoid of caveolin-1.

Rimmerman N, Bradshaw HB, Kozela E, Levy R, Juknat A, Vogel Z.

Br J Pharmacol. 2012 Apr;165(8):2436-49. doi: 10.1111/j.1476-5381.2011.01380.x.

15.

Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.

Kang JH, Goto T, Han IS, Kawada T, Kim YM, Yu R.

Obesity (Silver Spring). 2010 Apr;18(4):780-7. doi: 10.1038/oby.2009.301. Epub 2009 Oct 1.

16.

Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes.

De Gottardi A, Spahr L, Ravier-Dall'Antonia F, Hadengue A.

Liver Int. 2010 Nov;30(10):1482-9. doi: 10.1111/j.1478-3231.2010.02298.x.

PMID:
20602678
17.

N-Oleoyl glycine, a lipoamino acid, stimulates adipogenesis associated with activation of CB1 receptor and Akt signaling pathway in 3T3-L1 adipocyte.

Wang S, Xu Q, Shu G, Wang L, Gao P, Xi Q, Zhang Y, Jiang Q, Zhu X.

Biochem Biophys Res Commun. 2015 Oct 23;466(3):438-43. doi: 10.1016/j.bbrc.2015.09.046. Epub 2015 Sep 10.

PMID:
26365347
18.

Artemisia capillaris inhibits lipid accumulation in 3T3-L1 adipocytes and obesity in C57BL/6J mice fed a high fat diet.

Hong JH, Hwang EY, Kim HJ, Jeong YJ, Lee IS.

J Med Food. 2009 Aug;12(4):736-45. doi: 10.1089/jmf.2008.1240.

PMID:
19735172
19.

5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid.

Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, Parolaro D.

J Neurochem. 2008 Feb;104(4):1091-100. Epub 2007 Nov 17.

20.

Fargesin improves lipid and glucose metabolism in 3T3-L1 adipocytes and high-fat diet-induced obese mice.

Lee YS, Cha BY, Choi SS, Harada Y, Choi BK, Yonezawa T, Teruya T, Nagai K, Woo JT.

Biofactors. 2012 Jul-Aug;38(4):300-8. doi: 10.1002/biof.1022. Epub 2012 Jun 2.

PMID:
22674784

Supplemental Content

Support Center